Clinical trials: Advanced Malignant Tumor
Solid Tumor
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects with advanced malignancies with FGF/FGFR alterations.
- Trial name
- NCT04258527
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neoplasm
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
The purpose of this study is to evaluate the safety and preliminary efficacy of preladenant (MK-3814A) alone and in combination with pembrolizumab (MK-3475) (pembro) in participants with advanced solid tumors that have not…
- Trial name
- NCT03099161
- Testing
- preladenant, pembrolizumab
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid…
- Trial name
- NCT06163391
- Testing
- SOT201
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 40 people
- Sponsor
- SOTIO Biotech AG
Advanced Solid Tumor
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01283503
- Testing
- BKM120
- Where
- 2 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05494762
- Testing
- BGB-B167, Tislelizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- BeiGene
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Tumor Associated Lymph Node T Cell, Advanced Solid Tumor
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical…
- Conditions
- Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
- Trial name
- NCT06716619
- Testing
- Tumor Associated Lymph node T cell, Serplulimab Injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Neoplasms, Neoplasm Metastasis
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT05176665
- Testing
- EMB-01
- Where
- 14 sites in United States, China
- Volunteers
- 152 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase)…
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Trial name
- SPICE (NCT02636036)
- Testing
- enadenotucirev, nivolumab
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Akamis Bio
Advanced Gastrointestinal Stromal Tumor
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
- Trial name
- NCT00254267
- Testing
- AMG 706
- Volunteers
- 35 people
- Sponsor
- Amgen
Solid Tumor
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
- Trial name
- NCT03588039
- Testing
- Oraxol, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Athenex, Inc.
Solid Tumor
Clinical Study of ICP-192 in Solid Tumors Patients
Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.
- Trial name
- NCT03758664
- Testing
- ICP-192
- Where
- 7 sites in China
- Volunteers
- 56 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or RP2D of the orally administered PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162.
- Trial name
- NCT01337765
- Testing
- BEZ235 + MEK162
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Advanced Solid Tumor
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced…
- Trial name
- NCT05508100
- Testing
- IO-108, IO-108 + pembrolizumab, IO-108 + tislelizumab
- Where
- 14 sites in China
- Volunteers
- 38 people
- Sponsor
- Immune-Onc Therapeutics
Advanced Solid Tumors
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate Safety and tolerability of MASCT-I in patients with advanced solid tumors, either alone or in combination with chemical drugs or in combination with PD1 antibody.
- Trial name
- NCT03034304
- Testing
- MASCT-I, Ifosfamide, PD1 antibody
- Where
- 9 sites in China
- Volunteers
- 105 people
- Sponsor
- HRYZ Biotech Co.
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and…
- Trial name
- NCT03260179
- Testing
- AL3810
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Haihe Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.